Year: 2017

(Federal Official Gazette of February 20, 2017)On February 20 th , 2017, the Ministry of Health (MoH) issued Ordinance #542 of 2017 (Ordinance#542), reallocating the market shares of the PDPs involving monoclonal antibodies (adalimumabe,bevacizumab, infliximab, rituximab and trastuzumab) and etanercept. The market share of thePDPs was distributed between Tecpar, Fiocruz and Butantan, which are government-ownedpharmaceutical […]

After a long waiting, the Ministry of Health published the List of Strategic Products for the National Healthcare System (SUS), indicating the products eligible to receive proposals for PDPs in the 2017’ roundThe Ministry of Health’s Office published on January 27, 2017, a new list of strategic products for the SUS, Ordinance #252/2017, amended on […]